文献速递临床试验与 GCP组学、生物样本库与精准医学

加味阳和汤作为哮喘辅助治疗的疗效:随机双盲对照试验研究方案

Efficacy of Jia Wei Yang He formula as an adjunctive therapy for asthma: study protocol for a randomized, double blinded, controlled trial.
PubMed 文献 · Trials · 2018-07-04

本研究为多中心、平行组、随机双盲安慰剂对照试验,评估加味阳和汤(JWYH)联合常规治疗持续性哮喘的疗效,并探索气道微生物组与中药治疗的关系;计划入组240例,随访4个月,主要终点为治疗4周后ACT评分较基线的平均变化。

要点

  • 加味阳和汤联合常规治疗用于持续性哮喘,采用随机双盲安慰剂对照设计。
  • 主要疗效指标为治疗4周后ACT评分较基线的平均变化。
  • 次要指标包括FEV1、FVC、PEF及哮喘急性发作,并分析气道微生物组关联。

核心结论

  • 本试验旨在评估加味阳和汤联合常规治疗持续性哮喘的疗效及其与气道微生物组的关联。

研究设计与样本

  • 多中心、平行组、随机双盲、安慰剂对照试验,计划入组240例持续性哮喘患者,随机等分至高剂量加味阳和汤+常规治疗组、低剂量加味阳和汤+常规治疗组或安慰剂+常规治疗组,随访4个月。

关键数值与推荐

  • 主要疗效指标为治疗4周后ACT评分较基线的平均变化,基于改良意向性分析(mITT)比较三组。
  • 次要结局包括FEV1、FVC、PEF及哮喘急性发作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over the past two or three decades, the prevalence of asthma has significantly increased worldwide; therefore, effective treatment without side effects is of utmost importance. Traditional Chinese medicine (TCM) plays a vital role in reducing symptoms and improving the quality of life in persistent-asthma patients. The aim of this study is to evaluate the efficacy of the Jia Wei Yang He (JWYH) formula in the treatment of asthma and to explore the relationship between the airway microbiome and TCM treatment in asthma patients. METHODS/DESIGN: This multicenter, parallel-arm, randomized, double-blinded, placebo-controlled trial will assess the efficacy of JWYH in asthma patients with usual care. Persistent-asthma patients without life-threatening disease will be enrolled on a random basis and are equally assigned to a high- or a low-dose JWYH plus usual care group, or a placebo plus usual care group. Patients are followed up for 4 months. Accordingly, 240 patients will yield sufficient statistical power to determine a difference between groups. Based on modified intent-to-treat (mITT) analyses, the three groups will be compared at 4 weeks after the beginning of treatment. The primary efficacy measurement is the mean change in the Asthma Control Test (ACT) score from baseline to 4 weeks post treatment. Secondary outcomes include forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), and asthma exacerbations. This trial also includes analyses of the associations between airway microbiome and asthma treatment. DISCUSSION: In this study, a randomized clinical trial design is described. The results are based on several outcomes that estimate the efficacy of the JWYH formula and prospective links between the airway microbiome and asthma treatment. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03299322 . Registered on 3 October 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jiang W, Ma Z, Zhang H, et al. Efficacy of Jia Wei Yang He formula as an adjunctive therapy for asthma: study protocol for a randomized, double blinded, controlled trial. Trials. 2018. PMID: 29973284. doi:10.1186/s13063-018-2739-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。